CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
SF0166 Topical Ophthalmic Solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02914639
NCT02914639Phase 2Completed
CompareCT.gov

A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

OcuTerra Therapeutics, Inc.·interventional·Posted Sep 26, 2016·Updated Jun 7, 2023

In Brief

A Phase 2 clinical trial evaluating SF0166 Topical Ophthalmic Solution for Age-Related Macular Degeneration. Completed, enrolled 44 participants across 12 sites.

Detailed Summary

The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 26, 2016
Enrollment StartOct 5, 2016
Primary CompletionJun 26, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.8 years ago

Interventions

SF0166 Topical Ophthalmic Solutiondrug